ANTIVIRAL DRUGS ADVISORY COMMITTEE MEETING

January 10, 2001

SLIDES

NDA 21-227, Cancidas (caspofungin acetate) Injection, Merck Research Laboratories, proposed for treatment of invasive aspergillosis in patients refractory to, or intolerant of, other therapies.

Treatment of Aspergilosis, John R Perfect MD, Duke University Medical Center   ppt   htm

Safety and Efficacy of CANCIDAS (caspofungin acetate) in Invasive Aspergillosis, Eileen Navarro, MD, FDA   ppt   html

Merck Research Laboratories

Disclaimer

The statements contained in this document are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.

Introduction, Tamra Goodrow, PhD, Merck Research Laboratories

Caspofungin Development Program, Carole Sable, MD, Merck Research Laboratories

Concluding Remarks, Jeffrey Chodakewitz, MD, Merck Research Laboratories

Merck Backup Slides